Samuel Clark, MD
Family Medicine · Phoenix, AZNPI 1073506036
Payments from drug & device makers
Across 92 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$550
- Amgen$202
- Pfizer$136
- Abbott$88
- Novartis$61
- Astellas Pharma US Inc$61
- plus $538 from 18 others
What the payments were for
- Food & beverage$1,636100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $550 |
| Amgen | 11 | $202 |
| Pfizer | 7 | $136 |
| Abbott | 4 | $88 |
| Novartis | 3 | $61 |
| Astellas Pharma US Inc | 3 | $61 |
| Novo Nordisk | 3 | $51 |
| AstraZeneca | 3 | $51 |
| Radius Health, Inc. | 1 | $48 |
| Boehringer Ingelheim | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| GSK | 1 | $27 |
| Sanofi Pasteur Inc. | 1 | $27 |
| Merck | 2 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Teleflex LLC | 1 | $22 |
| Tolmar, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Phadia US Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
How this compares
$1,636 in reported general payments places this provider in the 75th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 197 | $228,932 |
| JardianceEmpagliflozin | 69 | $99,700 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $62,378 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $55,369 |
| TrulicityDulaglutide | 23 | $55,333 |
| OzempicSemaglutide | 46 | $52,367 |
| EliquisApixaban | 40 | $42,763 |
| FarxigaDapagliflozin Propanediol | 30 | $41,623 |
| XareltoRivaroxaban | 43 | $39,473 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $14,105 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $11,991 |
| BelsomraSuvorexant | 12 | $11,301 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $10,166 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $8,172 |
| Rosuvastatin Calcium | 318 | $5,492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $37 | $284,265220 claims |
| Boehringer IngelheimJardiance | $41 | $99,70069 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $27 | $86,64984 claims |
| Novo NordiskOzempic | $51 | $52,36746 claims |
| PfizerEliquis, Paxlovid | $136 | $45,62160 claims |
| AstraZenecaFarxiga | $51 | $41,62330 claims |
| Johnson & JohnsonXarelto | $15 | $39,47343 claims |
| MerckBelsomra | $25 | $11,30112 claims |
| AbbVieSynthroid | $550 | $2,28829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Phoenix
- Brock MerrittPhoenix$8.4M
- Douglas CunninghamPhoenix$4.9M
- Jeffrey ZacherPhoenix$2M
- Trisha TavaresPhoenix$1.6M
- David FrancykPhoenix$1.3M
- James BeachPhoenix$1.2M
- Peter LevinsPhoenix$971K
- Elysa ShawPhoenix$774K
- Mitchell EdelsteinPhoenix$741K
- Brian DedinskyPhoenix$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.